Glaxosmithkline Cons Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for GLAXOSMITHKLINE CONS, and what generic alternatives to GLAXOSMITHKLINE CONS drugs are available?
GLAXOSMITHKLINE CONS has thirteen approved drugs.
There are five US patents protecting GLAXOSMITHKLINE CONS drugs.
There are one hundred and nine patent family members on GLAXOSMITHKLINE CONS drugs in twenty-three countries and fourteen supplementary protection certificates in six countries.
Summary for Glaxosmithkline Cons
International Patents: | 109 |
US Patents: | 5 |
Tradenames: | 10 |
Ingredients: | 9 |
NDAs: | 13 |
PTAB Cases with Glaxosmithkline Cons as petitioner: | See PTAB cases with Glaxosmithkline Cons as petitioner |
Drugs and US Patents for Glaxosmithkline Cons
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | 8,347,879 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Glaxosmithkline Cons | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Glaxosmithkline Cons | NICORETTE | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 021330-001 | Oct 31, 2002 | OTC | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | 8,062,264 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Glaxosmithkline Cons | LAMISIL AT | terbinafine hydrochloride | SOLUTION;TOPICAL | 021124-001 | Mar 17, 2000 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Glaxosmithkline Cons
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Cons | NICORETTE | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 021330-001 | Oct 31, 2002 | 5,110,605 | ⤷ Try a Trial |
Glaxosmithkline Cons | LAMISIL AT | terbinafine hydrochloride | SPRAY;TOPICAL | 021124-002 | Mar 17, 2000 | 6,121,314*PED | ⤷ Try a Trial |
Glaxosmithkline Cons | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | 6,121,314 | ⤷ Try a Trial |
Glaxosmithkline Cons | LAMISIL | terbinafine | GEL;TOPICAL | 020846-001 | Apr 29, 1998 | 4,680,291 | ⤷ Try a Trial |
Glaxosmithkline Cons | ALLI | orlistat | CAPSULE;ORAL | 021887-001 | Feb 7, 2007 | 4,598,089 | ⤷ Try a Trial |
Glaxosmithkline Cons | EXCEDRIN (MIGRAINE) | acetaminophen; aspirin; caffeine | TABLET;ORAL | 020802-001 | Jan 14, 1998 | 4,943,565 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 60 mg | ➤ Subscribe | 2010-09-08 |
➤ Subscribe | Gum | 4 mg | ➤ Subscribe | 2013-01-22 |
➤ Subscribe | Gum | 2 mg | ➤ Subscribe | 2013-01-22 |
International Patents for Glaxosmithkline Cons Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2010246483 | ⤷ Try a Trial |
European Patent Office | 1723052 | ⤷ Try a Trial |
Mexico | PA04011108 | ⤷ Try a Trial |
Australia | 2003253367 | ⤷ Try a Trial |
Norway | 20044495 | ⤷ Try a Trial |
Denmark | 1501576 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glaxosmithkline Cons Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2506844 | 18C1022 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117 |
1305329 | SPC/GB08/026 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116 |
0024587 | 93C0136 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003 |
1519731 | 132013902182575 | Italy | ⤷ Try a Trial | PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527 |
2506844 | LUC00077 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
0129748 | 98C0042 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.